Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 4;14:51. doi: 10.3389/fnsys.2020.00051

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Yang, Zhan, Lin, Chu, Qiu and Lan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The mu-opioid receptor (MOR) antagonist CTOP abolishes fentanyl-mediated inhibition of facial stimulus-evoked responses in PCs. (A) Upper, example responses of a PC to air-puff stimulation (60 ms, 60 psi) in ACSF, CTOP, and CTOP (5 μM) + fentanyl (5 μM); lower, enlarged traces from the upper panel showing the effects of ACSF, CTOP (5 μM) and CTOP (5 μM) + fentanyl (5 μM) on sensory-evoked responses. (B) Left, summarized results showing the time course of 5 μM CTOP-induced changes in the amplitude of P1 (n = 6); Right, pooled data (n = 6) showing the time course of fentanyl-induced changes in the amplitude of P1 in the presence of CTOP. (C,D) Summarized data showing the normalized pause (C) and frequency (D) of SSs in ACSF, CTOP (5 μM), and CTOP (5 μM) + fentanyl (5 μM). (E,F) The bar graph shows the effects of CTOP (5 μM) and CTOP (5 μM) + fentanyl (5 μM) induced changes on the normalized amplitude (E) and AUC (F) of P1. *P < 0.05 vs. ACSF group.